Zobrazeno 1 - 10
of 155
pro vyhledávání: ''
Autor:
Harish Seethapathy, Paul Endres, Donald P. Lawrence, Meghan E. Sise, David A. Qualls, Halla Bates, Kerry L. Reynolds, Shahein Tajmir, Pedram Heidari
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Acute interstitial nephritis is an immune-related adverse event that can occur in patients receiving immune checkpoint inhibitor therapy. Differentiating checkpoint inhibitor-associated acute interstitial nephritis from other causes of acu
Autor:
Junying Zheng, Rui Wang, Megan Wind-Rotolo, Yan Feng, Richard Lee, Yuko Ishii, Akintunde Bello, Joshua Zhang, Xiao Shao, Amit Roy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Although several therapeutic options for patients with renal cell carcinoma (RCC) have been approved over recent years, including immune checkpoint inhibitors, considerable need remains for molecular biomarkers to assess disease prognosis.
Autor:
Riley Fadden, Gabriel E. Molina, Michael Dougan, Vikram Deshpande, Hui Zheng, Ryan J. Sullivan, Steven T. Chen, Michael S. Hughes
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Background Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically active glucocorticoids. Endoscopy
Autor:
Tatjana Vlajnic, Michael Dobbie, Marcus Vetter, Michel Bihl, Katharina Glatz, Florence Baettig, Jürgen Hench, Roberto Lopez, Celine Montavon, Stephan Frank, Viola Heinzelmann-Schwarz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has de
Autor:
Marcella Fassò, Carol O'Hear, Priti S. Hegde, Yijin Li, Leisha A. Emens, Sophia Maund, Maureen Berg, Jeanne Harrison, Luciana Molinero, Ching-Wei Chang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes
Autor:
Feng Li, Zhenqiang Sun, Dan Wang, Weitang Yuan, Li Yang, Aitian Li, Jinbo Liu, Zhiang He, Shasha Liu, Jingyao Lian, Weina Yu, Yi Zhang, Qian Wu
Publikováno v:
J Immunother Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Journal for Immunotherapy of Cancer
Background Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. The tumor microenvironment plays a key role in promoting the occurrence of chemoresistance in solid cancers. Effective targets to overcome resistance are necessar
Autor:
William D. Figg, Rajni Sharma, Cody J. Peer, Nicole D. Houston, Liang Cao, Christina M. Annunziata, Elise C. Kohn, Jung-Min Lee, Jane B. Trepel, Lekha Mikkilineni, Stanley Lipkowitz, Erin Nichols, Alexandra S Zimmer, Min-Jung Lee, Margaret E. Gatti-Mays, Ashley Cimino-Mathews
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, would complement anti-tumor acti
Autor:
James L. Gulley, Jane B. Trepel, Richard Schlegel, Clint T. Allen, Sunmin Lee, Siwen Hu-Lieskovan, Hong Ye, Julius Strauss, Paul E. Clavijo, Jeffrey Schlom, Damian Kovalovsky, Scott Norberg, Christian S. Hinrichs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Patients require frequent surgica
Autor:
Yufan Zhao, Lance Leopold, Geoffrey T. Gibney, Tara C. Mitchell, Brent A. Hanks, Robert C. Newton, Thomas F. Gajewski, Jeffrey S. Weber, Janet Maleski, Anthony J. Olszanski, Bartosz Chmielowski, Omid Hamid, Jose Lutzky
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyt
Autor:
Norman J. Lacayo, Teresa M. Bell, Jeffrey E. Rubnitz, Ching-Hon Pui, William E. Janssen, Huiyun Wu, Barbara Rooney, Kenneth Heym, Raul C. Ribeiro, Stanley Pounds, Rosa Nguyen, Barbara A. Degar, Brandon M. Triplett, Deborah Schiff, Hiroto Inaba, David Cullins, Wing Leung
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if adoptive transfer of natural killer (NK) ce